FDA Approves Lilly's Once-Weekly Basal Insulin Onswik for Type 2 Diabetes

The FDA has approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It joins Novo Nordisk's icodec as the second once-weekly basal insulin option available in the US market.

Why it matters

The FDA approval of Onswik gives clinicians a second once-weekly basal insulin option for adults with type 2 diabetes, following the earlier approval of Novo Nordisk's icodec. The pitch is straightforward: fewer injections, lower cognitive burden, potentially better adherence for patients who struggle with daily regimens. Those are real benefits, and the clinical trial data supporting the approval showed efficacy comparable to daily basal insulins with a manageable safety profile.

The more important question for health system leaders is not whether once-weekly insulin works, but how it gets integrated into existing diabetes management pathways without creating new gaps. Simplified dosing can improve adherence, but it can also reduce the frequency of patient-provider contact that catches early deterioration. Formulary decisions, patient selection criteria, and care team education will determine whether Onswik becomes a meaningful tool or a well-marketed addition to an already crowded insulin landscape.

What to watch

Whether payers move quickly to establish formulary placement and how Lilly prices Onswik relative to daily basal insulins, particularly given ongoing scrutiny of insulin affordability.